Investor Presentation – September 2014

Optimising mental capital through life

Makes Sense

Makes sense. Page 2

Interim Results - Financial Highlights

6 months to June 2014

6 months to June 2013

Year to Dec 2013

£’000 £’000 £’000

Sales

Clinical 1,588 1,277 2,497

Academic 874 592 1,493

Healthcare 32 149 158

2,494 2,018 4,148

Adjusted EBITDA* (391) (1,044) (1,955)

Loss before Tax (473) (1,493) (2,990)

Loss per share (pence) 2.9 14.4 21.3

Closing Cash Balance 1,593 3,320 2,261

* Adjusted for share-based payments and one-off H1 2013 IPO expenses

Confidential

Makes sense. Page 3

Cambridge Cognition

§  New therapeutic data §  New biomarkers §  Technology combinations §  New opportunities

§  Clinical development solutions §  Profiling of candidate drugs §  Manage patient enrolment

§  New Healthcare solutions §  Drug/Diagnostic combinations §  Early disease identification §  Community and domestic care

Managing Brain function & health for all age groups

Confidential

Cambridge Cognition: 1. Plays a leading role in the development of next

generation healthcare solutions for neuroscience and mental health

2. Develops world leading technology based products that serve to maximise the potential therapeutic benefit of treatment, enhance patient quality of life and, in so doing, reduce the burden on families and healthcare services.

3. Ensures the best possible practices and deliver the required quality of data

Makes sense. Page 4

A leading global provider of cognitive assessment software for use in:

•  Academic Research – Promoting products for use in Academic Research since 2002 •  Clinical Drug Trials - GCP compliant product for use in clinical trials since 2004

Quantifying cognitive function and optimizing mental health through research, treatment and diagnosis.

Confidential

Core Business

Makes sense. Page 5

The new 2014 plans are delivering success

Academic Business Unit

•  Year on Year sales up 47%

•  Digital marketing programs to drive new leads

implemented. 550 new bibliography registrations

in past 3 months

•  54% of the 2014 sales have been delivered via

sales within the world’s top 200 universities. 50%

higher average revenue from these sales

•  Direct contact to customers has significantly

increased during the last 6 months to 1,100 direct

contact by month

Clinical Trials Business Unit

•  Year on year sales increased by 25%

•  Single contract for £1.6M signed on June 1st

•  Cantab Connect launched on June 3rd with two products

focused on product safety

•  Securing leadership position in Abuse & Liability studies

with 7 won YTD and 13 in the pipeline

•  2 Phase II studies secured with pharma companies

•  Focus on building key account management function

•  Developing channel partnerships with CROs

Core Business

Healthcare Technology •  10,000 + Cantab Mobile assessments completed to date

•  Over 260 GP surgeries have used Cantab Mobile

•  1 in 4 Patients identified with signs of Mild Cognitive Impairment

•  500% increase in assessments conducted between August 2013 and August 2014

•  30 CCGs with who have purchased or running pilots and another 10 in discussion

Confidential

Makes sense. Page 6

Commercial strategy

●  Combining proven cognitive science with the

latest hosted solutions that enables

customers to access high value solutions

with simplicity

●  Create demand and value proposition for

cognitive testing into new markets and

settings

●  Delivering products through multiple

customer channels and potential for new

acquisitions with scale and efficiency

●  Capitalize on the shifting trend from

traditional pen and paper-based assessment

to hosted tools is acting as a driver for the

growth of the Cognitive assessment market

●  Growth in aging population and increase in

global research investment will act as major

drivers for the continual growth in market

size and commercial opportunity

Commercial Rules

1. Academic drives clinical sales.

2. Academic + Clinical lead to Healthcare

3. Sales can only be achieved from approved products

4. Prioritise sales through partners

5. Dedicated companion DX program a high priority

Confidential

Business Unit Route to Market

Academic Direct, e-commerce and partners

Clinical Direct and Partners

Healthcare Partners

Makes sense. Page 7

Cambridge Cognition Key account Marketing Programme

KEY STAGE 1 KEY STAGE 3 KEY STAGE 2

Value creation

Establish the need Development Production

Com

mer

cial

Opportunity Strategy Launch plan

1.  Market opportunity 2.  Unique sales drivers 3.  Competitive position 4.  Pricing options 5.  Product lifetime

1.  Product description 2.  Launch plan 3.  Route to market 4.  Promotion 5.  Tactical plan

1.  New products 2.  Line extensions 3.  New range 4.  New service 5.  Brand enhancement

Tech

nic

al

Performance Application Product

1.  Type of Brain Dx test 2.  Standard test or custom 3.  Degree of fit to customer 4.  Key Issues 5.  Development cost

1.  Final specification 2.  Quality requirements 3.  Custom definition 4.  Customer signoff 5.  Reproducibility

1.  Test format 2.  Format required 3.  Quality test 4.  Performance 5.  Time to market

•  Research proposal •  Material transfer

agreement

•  Supply agreement •  Contract terms •  Technology Access Fee •  Royalties

•  2-way NDA •  SCOPE •  Technical presentation •  Evaluation •  Timings •  Commercial proposal

Tool

s

Create one multi-disciplinary team

Establish a new Final Product team

Establish all relevant contacts in both parties

Team

s

Partnership

Confidential

Makes sense. Page 8

Business Development Channels

•  Products sold direct to Academic research and via digital marketing •  Data from Academic channel supports CT business unit •  Products sold direct to industry in CT unit •  CT unit provides direction for healthcare and e-health business - targets

clinical indication and diagnostic opportunities •  Healthcare and e-health business opportunities commercialised via partners

Healthcare and e-health

applications

Phase I Phase II

Phase III

Phase IV

Abuse Liability & Safety testing

CNS efficacy testing

Academic CNS characterisation & efficacy testing

CNS Clinical Research

Preclinical Research

CNS Research

Pharma/Biotech R&D

Research

Confidential

Makes sense. Page 9

Cantab Mobile 2014

“ The Dementia Challenge is huge, but there is hope in the extraordinary work of Cambridge Cognition, working to develop new tests for Alzheimer’s disease.”

Prime Minister David Cameron, Speaking at the G8 Dementia Summit

“Cantab Mobile is accurate, easy to use and quick to administer. The automatic scoring and instant reports give peace of mind to patients, their family and carers.” Joanne Liversidge, Dementia Nurse

Dr Miles Langdon, Dementia Lead, South Lincolnshire CCG

“We now have a tool that detects the earliest signs of dementia. This frees up capacity in the memory service and reduces stress for patients and their families.” Gary McFegan, Associate Director, NHS Commissioning Support

“The test was simple and reassuring. I would recommend it to anyone who is worried about their memory.” Patient in Walsall

“With more usage of Cantab Mobile, this memory test will become part of the norm – just like having a blood pressure check.”

Impact: Awareness and Advocacy

Confidential

Makes sense. Page 10

Impact: Adoption and Engagement

260+ GP Surgeries testing patients

Across 30 Healthcare Authorities

with interest

from 10 more

10,000+ patients received high quality cognitive assessment

500% increase in last 12 months

Detecting dementia

earlier

Saving NHS Time & Cost

Memory impairment detected in 25% of

patients

Early access to support

75% patients reassured avoiding referrals and costs

to the NHS

“ Our Dementia diagnosis rate has improved from 39% to 46.4%. Cantab Mobile has raised awareness of mild cognitive impairment and actively encouraged practices to assess patients earlier ” Havering NHS Clinical Commissioning Group

Cantab Mobile 2014

Confidential

Makes sense. Page 11

Since launching Cantab Mobile in the NHS, a range of international healthcare organisations have requested access to the technology. These include:

•  Pharmaceutical companies

•  Retail pharmacies

•  Patient registry services

•  Private healthcare providers

•  Care homes

•  Clinical research organisations

•  Employee health programmes

•  Healthcare provisioning specialists

•  Hospital systems

•  International research centres

These opportunities are analysed by the new corporate business development team.

Cantab Healthcare 2014

Impact: Beyond the NHS

The experience gained during the NHS pilot has reduced critical uncertainties. We now better understand the drivers and barriers to adoption and know that users will adopt and engage with the technology.

Confidential

Makes sense. Page 12

Value Creation

Research Clinical Phase 1 Clinical Phase 2 Clinical Phase 3 Healthcare Clinical Phase 4

Cambridge Cognition: Generates sales and profits from academic trials. Data supports future applications. Pharma exploits apps from Research. New science supports Camcog Business. Camcog science open to educate graduates

Phase 1 trials can open the door to phase 2 + if successful.

Cambridge Cognition: Phase 2 trials are profitable and secures Supporting data. Successful trials lead to phase 3 and further sales opportunities. Working with Pharma and Biotech further enhances the companies commercial relationships

Cambridge Cognition: New products coming out of clinical trials and available to patients can also lead to companion diagnostics and health management opportunities

Cambridge Cognition: Products which can be used in the management of health drive the highest value. The ultimate aim of the company is for their products to be used directly in managing the welfare of patients requiring cognition based testing

At all stages of evolution Cognition based testing can help the enrolment of patients for trials.

+ + > 3

Confidential

Cambridge Cognition's products will become commonly used as pivotal endpoints in phase III registration studies (to CONFIRM the properties of the drug). Late phase use will drive later adoption of the tests in clinical practice

Makes sense. Page 13

Leverage Cambridge Cognition technology and expertise to develop and commercialise sensitive, easy to

use assessments detecting the earliest signs of core disorders and syndromes for use in clinical and/or

home environments

•  Cambridge Cognition’s technology can de-centralise cognitive testing to identify treatment options for patients sooner and improve overall patient care.

•  The Technology Business unit should design and commercialise cognitive tests and medical software to measure: Presence of cognitive impairment arising from core diseases and syndromes. Detection can be used to screen potential patient populations in the community to accelerate treatment and care Impact of specific treatments - is a drug having the required effect? Is the drug having an adverse effect? Progression of a specific condition monitoring change over time. •  Products should be designed to run off a variety of hand held hardware platforms

The Healthcare Technology Business Unit

The Technology Business Unit will identify and exploit opportunities for tools to assess cognition in

pharmaceutical and healthcare settings beyond the formalised structure of the clinical trial and will access

these opportunities through commercial and technology partnerships

Cambridge Cognition will develop content and product concepts in two key areas of focus:

•  OEM/custom products for pharmaceutical companies identified through the Cambridge Cognition Clinical trials business

•  Healthcare applications for clinics and home use

Confidential

Makes sense. Page 14

Key Principles of the Technology Unit

Pharmaceutical partners

Healthcare opportunities The technology business unit will advance

partnered projects sourced via the Clinical Trials

business or from organic Healthcare

opportunities.

•  Identify and scope projects

•  Run pilot studies

•  Expect project attrition at scoping and pilot

stage

•  Focus on limited projects with near term

revenue

•  Align with technology and commercial partners

to pull product through

Revenue will be generated from milestone

payment and sales on product royalties

Pilot Studies

Technology and channel partners

Confidential

Makes sense. Page 15

Product selection and delivery

Stage of life Disease Management Cognitive Function Test Delivery

Children and Adolescents ADHD

Autism

Downs syndrome

Mid Life Depression

Schizophrenia

Traumatic Brain Injury

Cardiovascular disease

Oncology

Multiple sclerosis

Huntington's disease

Substance abuse

Older Adults Alzheimer's disease

Mild cognitive impairment

Parkinson's disease

Stroke

Memory

Attention

Executive Function

Decision Making

Social

Cloud Based solutions

iPads and tablets

Desktop computers

Smartphones

Embedded computing

Other

Confidential

Makes sense. Page 16

Healthcare Technology Unit Drives Growth of Corporate Value

Academic Research

Pharmaceutical CT

Healthcare technology

Direct Product Sales

Channel Partners/Licensees Enterprise

Value

Patient Population

Technology Advancement

Confidential

Makes Sense

© Cambridge Cognition 2014. All rights reserved.